AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.

Abdulmelik AytatliNeslisah BarlakFatma SanliHasan Onur CaglarBetul GundogduArzu TatarMichael IttmannOmer Faruk Karatas

Published in: Cellular oncology (Dordrecht) (2021)

From our data we conclude that AZD4547 may increase the impact of taxol during HNSCC treatment. We suggest AZD4547 as a therapeutic agent to overcome taxol-resistance.

Keyphrases

stem cells
signaling pathway
transcription factor
electronic health record
big data
machine learning
combination therapy
artificial intelligence